Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2025. For the year, on a core basis, the company expects revenue of ¥297,000 million, core operating profit of ¥55,000 million, core net profit for the year of ¥41,250 million and basic core earnings per share of ¥117.05. On IFRS basis, the company expects revenue of ¥297,000 million, operating profit of ¥44,500 million, net profit for the year of ¥33,500 million and basic earnings per share of ¥92.22.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,549 JPY | +0.68% | -3.13% | +10.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.18% | 3.55B | |
+38.69% | 723B | |
+34.28% | 595B | |
-4.49% | 369B | |
+20.24% | 332B | |
+2.12% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025